Compare APYX & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | APYX | IPHA |
|---|---|---|
| Founded | 1982 | 1999 |
| Country | United States | France |
| Employees | N/A | 174 |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 156.7M | 160.7M |
| IPO Year | 1995 | N/A |
| Metric | APYX | IPHA |
|---|---|---|
| Price | $3.27 | $1.63 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $7.00 | $5.00 |
| AVG Volume (30 Days) | ★ 90.9K | 15.7K |
| Earning Date | 04-03-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 19.40 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $9.36 | $28.31 |
| Revenue Next Year | $6.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.83 | $1.57 |
| 52 Week High | $4.50 | $2.63 |
| Indicator | APYX | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 37.92 | 41.03 |
| Support Level | $3.30 | $1.60 |
| Resistance Level | $4.40 | $1.88 |
| Average True Range (ATR) | 0.21 | 0.08 |
| MACD | -0.06 | -0.01 |
| Stochastic Oscillator | 19.39 | 13.67 |
Apyx Medical Corp is an energy technology medical device company. It specializes in developing, manufacturing, and marketing a range of cosmetic and surgical products and technologies, as well as related medical products used in doctor's offices, surgery centers, and hospitals. Its product offerings comprise Renuvion cosmetic technology, which offers plastic surgeons, facial plastic surgeons, and cosmetic physicians the ability to provide controlled heat to the tissue to achieve desired results. The J-Plasma system allows surgeons to operate with a high level of precision and virtually eliminates unintended tissue trauma. It operates in two segments namely: Advanced Energy and Original Equipment Manufacturing (OEM). Its Advanced Energy segment derives the majority of its revenue.
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.